Ambrx and Zhejiang Hisun sign deal over cancer treatment

USA-based clinical-stage biopharmaceutical company Ambrx and Chinese pharma firm Zhejiang Hisun Pharmaceutical (SSE: 600267) have announced a collaboration for the development and commercialization of bispecifics based on Ambrx’s technology for the treatment of cancer.

Hisun will have commercial rights to the products in China, while Ambrx will retain commercial rights outside of China and will be entitled to receive royalties on sales of the products in China. Hisun will manufacture the product to cGMP standards for clinical and commercial supplies on a global basis.

Lawson Macartney, chief executive of Ambrx, said: “This is a milestone for our company and a significant opportunity for us with Hisun as we develop bispecifics using our technology platform. Hisun represents a strong strategic partner with the right regulatory and manufacturing expertise. We believe that this collaboration is additional validation of our technology platform and its potential for many clinical applications.”